Finn
ONC Biotechnology · Oncology · Global pharma · Blood cancer · Thesis updated November 8, 2026

BRUKINSA fuels growth, but patents and clinical delays matter

01 Running thesis

A global leader facing clear hurdles

BeOne has built a global oncology business around BRUKINSA. The blood cancer therapy is the global revenue leader in the BTK inhibitor class. In Q3 2026, BRUKINSA global revenues reached $1.4 billion, which helped push total global product revenue to $1.9 billion, up 33% from the prior year. The U.S. market continues to dominate the growth profile.

The bull case focuses on sustained BRUKINSA growth and a maturing pipeline. BRUKINSA is capturing high numbers of new patient starts and benefits from real-world evidence showing a survival advantage. Beyond the core product, the solid tumor pipeline is advancing. Recent data presentations at ESMO for early-stage candidates show the pipeline is turning into a multi-modality engine.

The bear case centers on the vulnerability of relying heavily on one drug and the uncertainty of clinical data timelines. Zydus has filed to produce a generic version of BRUKINSA tablets, and AbbVie has sued over trade secrets related to a pipeline asset. Furthermore, the accelerated approval submission for the BTK degrader tacabrutideg in R/R CLL was delayed to mid-2027 following FDA requests for additional follow-up.

Nov 2026▲Q3 2026 product revenue grew 33% to $1.9 billion, and U.S. BRUKINSA sales exceeded $1 billion. However, the FDA requested more follow-up for tacabrutideg, pushing the filing to mid-2027.
Aug 2026▲Q2 2026 revenue grew 30% to $1.7 billion. The FDA approved BEQALZI, though the CELESTIAL-301 trial missed an early statistical goal.
May 2026▲Q1 2026 total global revenue rose 35% to $1.5 billion, and BRUKINSA revenue rose 38% to $1.1 billion. The thesis stays centered on BRUKINSA scale and the next sonrotoclax catalyst.
Feb 2026▲Management said BRUKINSA became number one in the U.S. and globally in 2025. The ZS fixed-time CLL plan became a clearer growth path.
Feb 2026▼The FY2025 filing added a new generic risk after Zydus filed an ANDA for BRUKINSA tablets. BeOne responded with a patent suit, making IP a bigger watch item.
Nov 2025▲Q3 2025 revenue grew 41% to $1.4 billion, and BRUKINSA grew 51% to $1.0 billion. The company also said BRUKINSA was the global revenue leader in BTK inhibitors.
Nov 2025▲Management raised 2025 revenue guidance to $5.1 billion to $5.3 billion. It also kept the plan to move about 10 new molecular entities into clinical trials by the end of 2025.
Aug 2025▲Q2 2025 revenue reached $1.3 billion, and BRUKINSA revenue was $950 million. The new tablet formulation improved the cost story.
02 Business model

Discover, build, and distribute globally

BeOne discovers, develops, and sells targeted cancer treatments. The company relies on its internal sales teams in major markets like the U.S. and Europe, and uses partnerships, such as its deal with Amgen, to sell in-licensed products in China. The company is actively investing in domestic capabilities, recently announcing a $300 million expansion of its clinical and commercial manufacturing site in Hopewell, New Jersey.

Product sales drive the vast majority of revenue. In Q3 2026, total product revenue reached $1.9 billion. BRUKINSA was the dominant source, but other drugs like TEVIMBRA and Amgen partnered products also contributed significantly. The U.S. remains the largest market, generating over $1 billion in the quarter.

The model relies heavily on clinical success and patent protection. Cancer drug markets are highly competitive. Companies must constantly fund new trials to expand approvals and defend against generic or biosimilar drugs. As BeOne scales, legal challenges from generic makers and supply chain complexities across the U.S., China, and Europe become larger factors.

03 Product portfolio

The core franchise and new bets

Growth engine

BRUKINSA

The primary revenue driver. It treats various blood cancers and generated $1.4 billion globally in Q3 2026.

Steady

TEVIMBRA

An immuno-oncology drug approved for certain esophageal and gastric cancers, generating $243 million in Q3 2026.

Option

BEQALZI

An FDA-approved BCL-2 inhibitor for relapsed or refractory mantle cell lymphoma.

Option

Sonrotoclax

A BCL2 inhibitor with early approvals in China. It is being tested in combinations aiming for fixed-time cancer treatments.

Option

Tacabrutideg

A BTK degrader targeting relapsed or refractory CLL, with an accelerated approval submission now planned for mid-2027.

Steady

Amgen in-licensed products

Products like XGEVA and KYPROLIS that generate meaningful sales in China through a strategic partnership.

04 Business segments

Revenue depends heavily on one drug

BRUKINSA74%growing fast
TEVIMBRA13%modest
Amgen in-licensed products9%modest
Other products4%growing fast

Mix is based on Q3 2026 total global product revenues of $1.9 billion. BRUKINSA represents approximately 74% of total sales.

05 Risk factors

What could derail the story

Generic BRUKINSA tablet challenge

High impact · Medium odds

Zydus filed an application seeking FDA approval for a generic version of BRUKINSA tablets, leading to a patent lawsuit in early 2026. A loss could shorten the protected life of BeOne's biggest drug.

We watchCourt rulings or settlements in the Zydus ANDA lawsuit.

AbbVie trade secret lawsuit

Medium impact · Medium odds

AbbVie claims BeOne misused trade secrets for the BGB-16673 BTK degrader program. Litigation can consume resources and potentially restrict a key pipeline asset.

We watchLegal updates, settlement terms, or injunctions in the AbbVie case.

Geopolitical supply chain stress

Medium impact · Medium odds

Operating across the U.S., China, and Europe exposes the company to tariffs and import controls. U.S. regulatory scrutiny on imported pharmaceuticals remains an ongoing concern, though domestic expansions mitigate some risk.

We watchChanges in U.S. tariffs or new regulatory actions on pharmaceutical imports.

Biosimilar competition for partnered drugs

Low impact · High odds

Management noted incoming biosimilar competition and volume-based procurement risks for XGEVA and KYPROLIS within their Amgen partnered portfolio, which will likely compress sales growth beyond 2026.

We watchRevenue trends and pricing pressure for the Amgen in-licensed product line.
06 Quick answers

In one breath

What does BeOne Medicines do?

BeOne Medicines discovers, develops, and sells targeted cancer treatments. Its most successful product is BRUKINSA, a therapy for blood cancers.

Why is BRUKINSA important?

BRUKINSA generated $1.4 billion in Q3 2026, representing about 74% of total product revenue. The company's financial success is heavily tied to this single drug.

What is happening with Tacabrutideg?

Tacabrutideg is an experimental BTK degrader. The company delayed its accelerated approval submission from late 2026 to mid-2027 following FDA requests for additional follow-up data.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. BeOne Medicines Q3 2026 earnings transcript
  2. BeOne Medicines Q2 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near BeOne Medicines AG in Finn's Biotechnology industry ranking.

Get started with Finn today